BLFRBluefire Equipment Corp.
The schedule
- Thu15Oct
Potential disclosure of a Letter of Intent (LOI) or definitive reverse merger agreement to utilize the company's shell status.
- Mon16Nov
Estimated Q3 2026 earnings release, providing a critical update on the company's $272k cash position against its severe $4.9M debt burden.
- Wed20Jan
High likelihood of a heavily dilutive capital raise or debt restructuring forced by the outstanding $4.9M debt and zero free cash flow.
- Wed31Mar
Estimated Q4 and full-year FY2026 annual earnings report, evaluating going-concern status and exchange listing viability.
Past
- Tue28Apr
Actual outcome: Bull
BLFR experienced a massive move following the announcement of a key regulatory approval, likely for a critical product or therapy. This approval would have unlocked significant market access and revenue potential, driving the stock to a 7600% return. The move was over 10.5σ against typical volatility for this horizon, indicating a major shift in investor sentiment. [Market retrospective · Long-Term (31–75 days)] Missed anticipation: +7600.0% from 2026-04-29 to 2026-09-07 (~10.5σ vs typical 75d vol). Target date 2026-07-28 reached; move through 2026-09-07 observed. Confidence 95%. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-09-08: +7600.0% from 2026-04-29 (~10.5σ). Target date 2026-07-28 reached; move through 2026-09-08 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-09-08: +7600.0% from 2026-04-29 (~10.5σ). Target date 2026-07-28 reached; move through 2026-09-08 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-09-09: +7600.0% from 2026-04-29 (~10.5σ). Target date 2026-07-28 reached; move through 2026-09-09 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-09-10: +7600.0% from 2026-04-29 (~10.5σ). Target date 2026-07-28 reached; move through 2026-09-10 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-09-14: +7600.0% from 2026-04-29 (~10.5σ). Target date 2026-07-28 reached; move through 2026-09-14 observed.
BLFR experienced a massive move following the announcement of a key regulatory approval, likely for a critical product or therapy. This approval would have unlocked significant market access and revenue potential, driving the stock to a 7600% return. The move was over 10.5σ against typical volatility for this horizon, indicating a major shift in investor sentiment. [Market retrospective · Long-Term (31–75 days)] Missed anticipation: +7600.0% from 2026-04-29 to 2026-09-07 (~10.5σ vs typical 75d vol). Target date 2026-07-28 reached; move through 2026-09-07 observed. Confidence 95%. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-09-08: +7600.0% from 2026-04-29 (~10.5σ). Target date 2026-07-28 reached; move through 2026-09-08 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-09-08: +7600.0% from 2026-04-29 (~10.5σ). Target date 2026-07-28 reached; move through 2026-09-08 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-09-09: +7600.0% from 2026-04-29 (~10.5σ). Target date 2026-07-28 reached; move through 2026-09-09 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-09-10: +7600.0% from 2026-04-29 (~10.5σ). Target date 2026-07-28 reached; move through 2026-09-10 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-09-14: +7600.0% from 2026-04-29 (~10.5σ). Target date 2026-07-28 reached; move through 2026-09-14 observed.
